Trial Outcomes & Findings for Topical Antimicrobial Effectiveness Testing (NCT NCT01366417)

NCT ID: NCT01366417

Last Updated: 2025-12-11

Results Overview

Antimicrobial efficacy will be measured by the change (+/-) in bacterial count on the skin 30 seconds after a single application of test material relative to the baseline bacterial count.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

25 participants

Primary outcome timeframe

30 seconds after treatment

Results posted on

2025-12-11

Participant Flow

First subject/first visit: May 12, 2011 Last subject/last visit: June 8, 2011

43 subjects entered screening phase.25 subjects had qualifying treatment day baseline counts and completed the study.

Participant milestones

Participant milestones
Measure
ChloraPrep One Step and 70% Isopropyl Alcohol
All subjects received a single topical treatment with both the test article (ChloraPrep One Step) and the positive control (Isopropyl Alcohol)
Overall Study
STARTED
43
Overall Study
Signed Informed Consent
43
Overall Study
Completed Screen Visit
33
Overall Study
Completed Treatment Visit
28
Overall Study
Completed the Study
28
Overall Study
Discontinued Prior to Treatment
5
Overall Study
Excluded From Analysis
3
Overall Study
COMPLETED
25
Overall Study
NOT COMPLETED
18

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Topical Antimicrobial Effectiveness Testing

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ChloraPrep One Step and 70% Isopropyl Alcohol
n=28 Participants
All subjects received a single topical treatment with both the test article (ChloraPrep One Step) and the positive control (Isopropyl Alcohol)
Age, Categorical
<=18 years
0 Participants
n=237 Participants
Age, Categorical
Between 18 and 65 years
28 Participants
n=237 Participants
Age, Categorical
>=65 years
0 Participants
n=237 Participants
Age, Continuous
36 years
STANDARD_DEVIATION 16.71105 • n=237 Participants
Sex: Female, Male
Female
16 Participants
n=237 Participants
Sex: Female, Male
Male
12 Participants
n=237 Participants
Region of Enrollment
United States
28 participants
n=237 Participants

PRIMARY outcome

Timeframe: 30 seconds after treatment

Population: subjects whose treatment day baseline microbial count met the qualification criteria and completed all assessments.

Antimicrobial efficacy will be measured by the change (+/-) in bacterial count on the skin 30 seconds after a single application of test material relative to the baseline bacterial count.

Outcome measures

Outcome measures
Measure
ChloraPrep One Step
n=25 Participants
All subjects received a single topical application of ChloraPrep One Step.
70% Isopropyl Alcohol
n=25 Participants
All subjects received a single topical application of 70% Isopropyl Alcohol.
Antimicrobial Efficacy
2.21 log 10 colony forming units / cm^2
95% Confidence Interval 0.1332 • Interval 1.95 to 2.48
2.25 log 10 colony forming units / cm^2
95% Confidence Interval 0.1332 • Interval 1.99 to 2.51

PRIMARY outcome

Timeframe: 10 minutes after treatment

Population: Subjects whose Treatment Day Baseline bacterial counts met qualification criteria

Antimicrobial efficacy will be measured by the change (+/-) in bacterial count on the skin 10 minutes after a single application of test material relative to the baseline bacterial count.

Outcome measures

Outcome measures
Measure
ChloraPrep One Step
n=25 Participants
All subjects received a single topical application of ChloraPrep One Step.
70% Isopropyl Alcohol
n=25 Participants
All subjects received a single topical application of 70% Isopropyl Alcohol.
Antimicrobial Efficacy
2.65 log 10 colony forming units / cm^2
Interval 2.39 to 2.92
2.60 log 10 colony forming units / cm^2
Interval 2.33 to 2.86

Adverse Events

ChloraPrep One Step and 70% Isopropyl Alcohol

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jennifer Raeder-Devens

CareFusion

Phone: 847-454-4939

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place